Short answer
XOMA Royalty Corp (XOMA) filed an 8-K current report with the SEC on April 27, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Ligand to acquire XOMA Royalty for $39.00 cash per common share plus contingent value rights tied to RemainCo assets.
XOMA Royalty Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Ligand to acquire XOMA Royalty for $39.00 cash per common share plus contingent value rights tied to RemainCo assets
- Perpetual Series A and B preferred shares redeemed with accrued unpaid dividends; Series X converts into merger consideration
- Closing requires majority stockholder approval, antitrust clearance, holding-company reorganization, and CVR spin; no financing condition
- Supporting stockholders controlling approximately 47% of shares agreed to vote for the transaction, materially improving approval certainty
- $40 million termination fee applies under specified scenarios, including a superior proposal or board recommendation change
Item 8.01 · Other Events
- Merger Agreement executed April 27, 2026, initiating Parent’s proposed acquisition of XOMA Royalty
- Transaction requires XOMA Royalty stockholder approval and potentially regulatory approvals before closing
- Definitive proxy statement will provide transaction terms, voting recommendations, and participant-interest disclosures
- Key risks include competing offers, closing failure, integration challenges, litigation, and significant transaction costs
- Investors should evaluate the definitive proxy statement before voting; completion timing remains uncertain
Item EX-99.1 · Exhibit EX-99.1
- Ligand to acquire XOMA for $39.00 cash per share, valuing equity at approximately $739 million
- XOMA holders receive one CVR per share tied to 75% of net proceeds from pending TREMFYA litigation
- Portfolio expands by over 120 assets, seven commercial products, and 14 late-stage development programs
- Ligand raises 2026 revenue guidance to $270–$310 million and adjusted EPS guidance to $8.50–$9.50
- Closing targeted for Q3 2026, subject to shareholder and regulatory approvals; transaction expected to add $1.50 adjusted EPS in 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other XOMA Royalty Corp 8-K filings
Get the next XOMA 8-K as it lands
Follow XOMA for push alerts, or ask the research agent what this filing means.